riple negative breast cancer, or TNBC, and sarcomas. GPR174 Program The company is conducting medicinal chemistry to optimize compounds against GPR174, a GPCR that is linked to autoimmunity. GPR183 Program The company is conducting medicinal chemistry to optimize compounds against GPR183, a GPCR that is linked to osteoporosis and Epstein-Barr virus, or EBV, infections and associated diseases. Antibody Platform The company’s proprietary ex vivo platform for the discovery of monoclonal antibodies, which was in-licensed from the University of Washington (UW) and then further developed by its scientists, utilizes a chicken B-cell lymphoma cell line. The company holds a worldwide exclusive license to patent rights related to its antibody platform from UW. Sales In the U.S., the company sells OMIDRIA through a limited number of wholesalers that distribute the product to ASCs and hospitals. Three of the company’s major distributors - AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation - together with entities under their common control each accounted for 10% or more of its total revenue in 2015. Research and development For the year ended December 31, 2015, the company’s research and development expenses were $48.4 million. Intellectual Property As of March 8, 2016, the company owned or held worldwide exclusive licenses to a total of 55 issued patents and 72 pending patent applications in the U.S. and 310 issued patents and 327 pending patent applications in foreign markets directed to therapeutic compositions and methods related to its development programs. As of March 8, 2016, the company’s patent portfolio included 9 U.S. and 50 foreign issued or allowed patents, and 14 U.S. and 72 foreign pending patent applications, directed to its PharmacoSurgery products and development programs. The company’s issued PharmacoSurgery patents have terms that would expire as late as October 23, 2033 for OMIDRIA, September 24, 2022 for OMS103, and July 16, 2029 for OMS201, and, if pending patent applications are issued, as late as November 30, 2035 for OMIDRIA, August 3, 2032 for OMS103, and March 17, 2026 for OMS201. The company’s pending PharmacoSurgery patent applications are directed to combinations of agents, drawn from therapeutic classes, such as pain and inflammation inhibitory agents, spasm inhibitory agents, vasoconstrictive agents, mydriatic agents and agents that reduce intraocular pressure, that are used in ophthalmologic procedures, including intraocular procedures (OMIDRIA), arthroscopic procedures (OMS103), and urologic procedures, including ureteroscopy (OMS201), as well as covering the specific combinations of agents included in each of these products and product candidates. OMIDRIA-Ophthalmology: OMIDRIA is encompassed by its PharmacoSurgery patent portfolio. As of March 8, 2016, the company owned 4 issued U.S. patents and 4 pending U.S. patent applications and 31 issued patents and 55 pending patent applications in foreign markets that are directed to OMIDRIA. OMS103-Arthroscopy: OMS103 is encompassed by the company’s PharmacoSurgery patent portfolio. As of March 8, 2016, the company owned 3 issued U.S. patents, 4 pending U.S. patent applications, and 12 issued patents and 16 pending patent applications in foreign markets, that are directed to OMS103. OMS201-Urology: OMS201 is encompassed by the company’s PharmacoSurgery patent portfolio. As of March 8, 2016, the company owned one issued U.S. patent, two pending U.S. patent applications, and an additional seven issued patents and two pending patent applications in foreign markets that are directed to OMS201. MASP-2 Program - OMS721: The company holds worldwide exclusive licenses to rights in connection with MASP-2, the antibodies targeting MASP-2 and the therapeutic applications for those antibodies from the University of Leicester, MRC and Helion. As of March 8, 2016, the company exclusively controlled 13 issued patents and 22 pending patent applications in the U.S., and 61 issued patents and 87 pending patent applications in foreign markets, related to its MASP-2 program and associated compl
omeros corp (OMER:NASDAQ GM)
201 Elliott Avenue West
Seattle, WA 98119
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for OMER.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact OMEROS CORP, please visit www.omeros.com. Company data is provided by Capital IQ. Please use this form to report any data issues.